[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-carcinoma":34},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,52,78,102,123,145,166,197,218,238,257,278,300,320,360,383,404,442,473,490,511,532,549,577,594],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100592628","the-vanguard-study-testing-a-new-way-to-screen-for-cancer-100592628",false,"NCT06995898","The Vanguard Study: Testing a New Way to Screen for Cancer","Inclusion Criteria:\n\n* Ages 45-75 years old\n* Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment\n* Agree to allow collection of information from their medical records for study-related purposes\n* Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic\n\n  * Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion\n\nExclusion Criteria:\n\n* Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years\n\n  * Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible\n* Ongoing cancer diagnostic work-up\n* Ongoing participation in another study of an investigational cancer screening test or technology\n* Currently breastfeeding or pregnant, or planning to become pregnant in the next year",true,"ALL","45 Years","75 Years",{"count":21,"type":22},24000,"ESTIMATED","INTERVENTIONAL",[25],"NA","The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).",[28,29,30,31,32,33,34,35,36,37,38],"Bladder Carcinoma","Breast Carcinoma","Colorectal Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Liver Carcinoma","Lung Carcinoma","Malignant Solid Neoplasm","Ovarian Carcinoma","Pancreatic Carcinoma","Prostate Carcinoma","RECRUITING","2026-06-30",{"date":42,"type":43},"2026-07-01","ACTUAL",{"date":45,"type":43},"2025-06-18",{"date":47,"type":22},"2029-06-30",{"name":49,"class":50},"National Cancer Institute (NCI)","NIH",38,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100470538","improving-decision-making-encounters-in-lung-cancer-using-a-low-literacy-conversation-tool-100470538","NCT05407168","Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool","Improving Decision-Making Encounters in Lung Cancer (I DECide) II: A Randomized Control Trial Of A Low-Literacy Conversation Tool","iDECIDE","Inclusion Criteria:\n\n* AIM 1: Suspected lung cancer\n* AIM 1: English fluency\n* AIM 1: \\> 6-month life expectancy\n* AIM 1: Score of ≥ 3 on the cognitive impairment screener\n* AIM 2 PARTICIPANTS: Participation in Aim 1\n* AIM 2 CLINICIANS: Discussing lung cancer treatment decisions with Aim 1 participants","18 Years","99 Years",{"count":63,"type":22},300,[25],"This clinical trial evaluates the effectiveness of a conversation tool on patient-centered health and decision-making outcomes in patients with lung cancer making treatment decisions. This research is being conducted to help doctors understand the information patients need to participate in shared decision-making about their lung cancer treatment options. The focus of this research is to study how patients choose lung cancer treatment options and the information needed to make that choice, with a focus on patients with lower health literacy.",[34],"2026-06-22",{"date":69,"type":43},"2026-06-25",{"date":71,"type":43},"2022-10-31",{"date":73,"type":22},"2027-12-31",{"name":75,"class":76},"OHSU Knight Cancer Institute","OTHER",4,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":16,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100644107","investigating-the-feasibility-and-acceptability-of-an-innovative-interdisciplinary-supportive-care-program-couples-coping-together-against-cancer-100644107","NCT07664579","Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer","Inclusion Criteria:\n\n* Have received a diagnosis of a primary brain tumor (glioblastoma), or other cancers (breast, lung, etc.)\n* Are new patients to City of Hope (COH) (all sites) or receive at least some of their care at City of Hope- Duarte Campus (care is defined as: procedures, consults, laboratories, imaging, surgery, and\u002For treatment)\n* The patient is in a committed relationship\u002Fpartnership with a partner and the partner is available and willing to participate\n* Are English or Spanish speaking\n* ≥ 18 years of age\n* Have access to a smartphone, computer\u002Flaptop or internet connection to complete all study procedures\n\nExclusion Criteria:\n\n* Significant cognitive impairment\n* Inpatient psychiatric treatment for severe mental illness or overt signs of severe psychopathology (e.g., psychosis)\n* Visual, hearing, voice, or motor impairment that prevents completion of study procedures as evidenced by clinical judgment\n* Committed partners will be excluded from the study if they:\n\n  * Refuse to complete informed consent\n  * Have cognitive impairment\n  * Have severe mental illness that would prevent informed consent and completion of study activities as evidenced by clinical judgment",{"count":85,"type":22},160,"OBSERVATIONAL","This study evaluates how useful and acceptable the components of the \"Couples Coping Together Against Cancer\", referred to as \"The Program\", are to the participants with cancer.",[89,90,34,35,91],"Anatomic Stage IV Breast Cancer AJCC v8","Glioblastoma","Metastatic Breast Carcinoma","2026-06-18",{"date":94,"type":43},"2026-06-24",{"date":96,"type":43},"2024-07-05",{"date":98,"type":22},"2026-11-16",{"name":100,"class":76},"City of Hope Medical Center",1,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":101},"100635525","home-based-respiratory-muscle-training-and-aerobic-exercise-programs-to-improve-lung-health-in-current-and-former-cigarette-smokers-100635525","NCT07553819","Home-Based Respiratory Muscle Training and Aerobic Exercise Programs to Improve Lung Health in Current and Former Cigarette Smokers","Effects of Respiratory Muscle Training and Aerobic Exercise on Lung Health in Smokers: A Pilot Parallel-Group Study for Lung Cancer Prevention","Inclusion Criteria:\n\n* Age ≥ 50 years old\n* Current smoker with a ≥ 20-pack-years history\n* Former smoker within the past 15 years, with a history of ≥ 20 pack-years (CT scan cohort only)\n* Participant must be able to speak, read and comprehend English language\n* Cognitively capable of following direction and performing the intervention\n* Understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Any previous lung cancer diagnoses and or undergoing treatment for any cancer\n* Recent pneumonia, bronchitis, or other inflammatory conditions in the lungs, including but limited to chronic obstructive pulmonary disease (COPD) and\u002For asthma exacerbation within the previous 6 months\n* Have uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study intervention","50 Years",{"count":111,"type":22},200,[25],"This clinical trial studies whether home-based respiratory muscle training (RMT) and aerobic exercise (AE) programs can be used to improve lung health in current and former cigarette smokers. Lung cancer, the leading cause of cancer death, is overwhelmingly caused by exposure to cigarette smoke. Research suggests that daily activity reduces lung cancer risk in current and former smokers. However, current and former smokers are generally not active and new approaches to improve lung health are needed. During the home-based RMT program, participants use a handheld device to complete breathing exercise sessions consisting of breathing in and out against adjustable resistance. During the home-based AE program, participants complete aerobic exercises using a stationary bike working at a moderate workload against adjustable resistance. The home-based RMT and AE programs may be effective ways to strengthen the breathing muscles, which may improve lung health in current and former cigarette smokers.",[34],"NOT_YET_RECRUITING",{"date":67,"type":43},{"date":118,"type":22},"2026-08-01",{"date":120,"type":22},"2029-05-01",{"name":122,"class":76},"Roswell Park Cancer Institute",{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":16,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":101},"100532494","connecting-to-lungcare-100532494","NCT06213532","CONNECTing to LungCare","Inclusion Criteria:\n\n* English, Spanish and Cantonese speaking\n* Age \\>= 18 years old\n* Primary care patients at the University of California, San Francisco (UCSF) General Internal Medicine (GIM) clinics\n* Must be current smokers and\u002For candidates for Lung Cancer Screening (LCS).\n\nKey Informant Interviews:\n\n\\- Must be working in one of the clinics participating in CONNECTing to LungCare.\n\nExclusion Criteria:\n\n* Not a current smoker",{"count":130,"type":22},152,[25],"This study evaluates a smoking cessation intervention (CONNECTing to LungCare) for improving shared decision-making conversations about smoking cessation and lung cancer screening between patients and providers. Shared decision making is a patient care model in which providers offer information regarding risks and benefits, patients express their values and preferences, and then healthcare decisions are jointly discussed between the patient and provider. Patient education, aided by decision support tools, can increase patients' knowledge, decrease their decisional conflict, promote decision making, and improve the patients' perception of risk. CONNECTing to LungCare is an interactive education intervention that addresses lung cancer screening and smoking cessation and provides participants with a tailored summary that may make them more likely to have shared decision-making discussions with their providers about smoking cessation and lung cancer screening.",[134,135,34],"Smoking Cessation","Cigarette Smoking-Related Carcinoma","2026-06-11",{"date":138,"type":43},"2026-06-15",{"date":140,"type":43},"2024-12-03",{"date":142,"type":22},"2026-11-30",{"name":144,"class":76},"University of California, San Francisco",{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":16,"sex":17,"minAge":109,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":164,"locationsCount":101},"100630683","a-restorative-justice-based-lung-cancer-screening-decision-making-support-intervention-tailored-for-black-individuals-to-increase-lung-cancer-screening-among-black-community-members-restore-trial-100630683","NCT07490860","A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial","Integrating Restorative Practices to Enhance Shared Decision-Making and Uptake of Lung Cancer Screening in Black Community Members (RESTORE)","Inclusion Criteria:\n\n* Identify as Black or African American\n* Between ages 50-77\n* Self-reported 20-pack year smoking history\n* Ongoing commercial tobacco use within the past 15 years\n* Proficiency in the English language\n\nExclusion Criteria:\n\n* Has a documented chest CT within the past one year\n* Personal history of lung cancer or symptoms associated with lung cancer","77 Years",{"count":154,"type":22},45,[25],"This clinical trial develops and studies whether a restorative justice-based lung cancer screening (LCS) decision-making support intervention tailored for Black individuals increases LCS among Black community members. Lung cancer remains the leading cause of cancer deaths among Black men and women. LCS with yearly low-dose chest computed tomography (CT) is recommended for people with current or recent tobacco use (within 15 years) who are aged 50-80 with at least a 20 pack-year smoking history. LCS lowers lung cancer death by 20%; however, data shows that LCS completion remains low among minority groups in the United States. The restorative justice-based LCS decision-making support intervention in this trial has been specifically tailored to meet the needs of Black individuals. It is designed to reduce racial unfairness by promoting trust, shared understanding, and empowerment in clinical decision making while addressing the social and historical circumstances of health inequalities. This may be an effective way to increase LCS among Black community members.",[34],"2026-06-10",{"date":160,"type":43},"2026-06-12",{"date":42,"type":22},{"date":163,"type":22},"2026-12-31",{"name":165,"class":76},"Fred Hutchinson Cancer Center",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":195,"locationsCount":101},"100423117","phase-2-canakinumab-for-the-prevention-of-lung-cancer-the-can-prevent-lung-trial-100423117","NCT04789681","Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial","Single Arm Phase II Trial Using Canakinumab for the Prevention of Lung Cancer (Can-Prevent-Lung)","Inclusion Criteria:\n\n* The participant (or legally authorized representative if applicable) provides written informed consent for the trial\n* Participants are eligible to be included in the study if one of the following criteria applies:\n\n  * Patients with no history of lung cancer, who have persistent IPNs (on two computed tomography \\[CT\\] scans at least 3 months apart with no evidence of shrinkage or regression) detected by low dose computed tomography \\[LDCT\\]-guided lung cancer screening or imaging studies for other reasons (incidentalomas) with 10-30% cancer probability by Brock University cancer prediction equation as following\n  * Patients with no history of lung cancer, who have persistent IPNs (on two CT scans at least 3 months apart with no evidence of shrinkage or regression) detected by LDCT-guided lung cancer screening or imaging studies for other reasons (incidentalomas) with \\> 30% cancer probability by Brock University cancer prediction equation as following, but biopsy showed no clear evidence of malignancy\n  * Patients with history of stage I-III non-small cell lung cancer (NSCLC), who have completed treatment with curative intent, who have persistent IPNs (on two CT scans at least 3 months apart with no evidence of shrinkage or regression) with 5-30% cancer probability by Brock University cancer prediction equation as following\n  * Patients with history of stage I-III NSCLC, who have completed treatment with curative intent, who have persistent IPNs (on two CT scans at least 3 months apart with no evidence of shrinkage or regression) with \\> 30% cancer probability by Brock University cancer prediction equation, but biopsy showed no clear evidence of malignancy\n* At least 18 years of age on the day of signing informed consent\n* A male participant must agree to use a contraception during the treatment period plus an additional 6months (a spermatogenesis cycle) after the last dose of study treatment and refrain from donating sperm during this period\n* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n  * Not a woman of childbearing potential (WOCBP) OR\n  * A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 6 months after study treatments with risk of genotoxicity after the last dose of study treatment\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the start of study treatment\n* Absolute neutrophil count (ANC) \\>= 1500\u002FuL (collected within 10 days prior to the start of study treatment)\n* Platelets \\>= 100 000\u002FuL (collected within 10 days prior to the start of study treatment)\n* Hemoglobin \\>= 9.0 g\u002FdL or \\>= 5.6 mmol\u002FL (collected within 10 days prior to the start of study treatment)\n\n  * Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.\n* Creatinine =\\\u003C 1.5 x upper limit or normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate (GFR) can also be used in place of creatinine or creatinine clearance \\[CrCl\\]) \\>= 30 mL\u002Fmin for participant with creatinine levels \\> 1.5 x institutional ULN (collected within 10 days prior to the start of study treatment)\n\n  * Creatinine clearance (CrCl) should be calculated per institutional standard\n* Total bilirubin =\\\u003C 1.5 x ULN OR direct bilirubin =\\\u003C ULN for participants with total bilirubin levels \\> 1.5 x ULN (collected within 10 days prior to the start of study treatment)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) =\\\u003C 2.5 x ULN (collected within 10 days prior to the start of study treatment)\n\nExclusion Criteria:\n\n* A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication\n* Has received prior therapy with an anti-IL1beta\n* Has a known additional malignancy that is progressing or has required active treatment within the past year. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded\n* Has an active infection requiring systemic therapy\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the screening visit through 6 months after the last dose of trial treatment\n* Is receiving the following therapies during the screening and treatment phases (including retreatment for post-complete response relapse) of this trial: antineoplastic systemic chemotherapy or biological therapy, immunotherapy not specified by this protocol, chemotherapy not specified by this protocol, investigational agents other than canakinumab\n* Has received live vaccines within 30 days prior to first dose of study treatment and while participating in the study. Examples of live vaccines include but are not limited to: measles, mumps, rubella, varicella\u002Fzoster, yellow fever, rabies, Bacillus Calmette-Guerin (BCG) and typhoid vaccine. (Note: Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (eg FluMist are live attenuated vaccines are not allowed)",{"count":174,"type":22},50,[176],"PHASE2","This phase II trial studies the effects of canakinumab in preventing lung cancer in patients who have high-risk pulmonary nodules. Canakinumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving canakinumab may prevent the development of lung cancer.",[34,179,180,181,182,183,184,185,186,187,188,189,190],"Stage I Lung Cancer AJCC v8","Stage IA1 Lung Cancer AJCC v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Stage IB Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8",{"date":160,"type":43},{"date":193,"type":43},"2021-07-20",{"date":73,"type":22},{"name":196,"class":76},"M.D. Anderson Cancer Center",{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":217,"locationsCount":101},"100132279","data-collection-for-the-assessment-of-acute-and-late-normal-tissue-in-patients-treated-with-proton-therapy-100132279","NCT00991094","Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy","Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults","Inclusion Criteria:\n\n* All patients scheduled for radiation treatment with protons at UTMDACC are eligible for this protocol\n* Patients must sign a study-specific consent form prior to study entry\n\nExclusion Criteria:\n\n* Patients who are unable or unwilling to attend the required periodic follow-ups either at M.D. Anderson or at a different site",{"count":205,"type":22},5000,"This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.",[29,31,208,209,210,34,211,212,35],"Genitourinary System Carcinoma","Head and Neck Carcinoma","Hematopoietic and Lymphoid Cell Neoplasm","Malignant Central Nervous System Neoplasm","Malignant Digestive System Neoplasm",{"date":160,"type":43},{"date":215,"type":43},"2005-05-27",{"date":73,"type":22},{"name":196,"class":76},{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":16,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":234,"leadSponsor":236,"locationsCount":237},"100606472","tailored-patient-navigation-to-improve-the-uptake-of-lung-cancer-screening-in-tribal-communities-in-western-washington-state-sacred-lungs-trial-100606472","NCT07176000","Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington State, SACRED LUNGS Trial","Strengthening Awareness and Community Resources for Early Detection of Lung Cancer Through Navigation Guided Screening Trial (SACRED LUNGS Aims 1.2-3)","Inclusion Criteria:\n\n* AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Between ages 50-77\n* AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Self-reported 20-pack year smoking history\n* AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Ongoing commercial tobacco use within the past 15 years\n* AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Seen by a PCP at a participating clinic (South Puget Intertribal Planning Agency \\[SPIPA\\] or Muckleshoot) within the past three years\n\n  * Potential participants who want to establish care at an eligible clinic will be connected to a PCP\n* AIM 2 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: At least 18 years of age\n* AIM 2 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Affiliation with Muckleshoot or SPIPA (one of the 6 community partnering clinics) as a provider, or supportive staff member\n* AIM 2 PATIENT SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Patient participated in the aim 1.2 trial\n* AIM 3 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: At least 18 years of age\n* AIM 3 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Affiliation with Muckleshoot or SPIPA (one of the 6 community partnering clinics) as a provider, or supportive staff member\n* AIM 3 PATIENT SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Patient participated in the aim 1.2 trial\n\nExclusion Criteria:\n\n* AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Has had a documented chest CT within the past one year\n* AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Personal history of lung cancer or symptoms associated with lung cancer",{"count":226,"type":22},237,[25],"This clinical trial studies whether tailored patient navigation (PN) works to improve the uptake of lung cancer screening (LCS) in tribal communities in western Washington state. Lung cancer is the leading cause of cancer death in the United States among American Indian (AI) and Alaska Native (AN) people, and the incidence of lung cancer is higher in this population in the Northern and Southern Plains, Alaska, and Pacific Coast regions. In Washington state, AI\u002FAN people also have twice the rate of commercial cigarette smoking than the overall population. LCS with annual low-dose chest computed tomography (CT) can reduce lung cancer death and is recommended in people 50-80 years of age with current or recent (within 15 years) tobacco use and a 20 pack-year or greater smoking history. Despite this, AI and AN people are less likely to receive LCS which may be due to barriers they face making it difficult to receive LCS. PN services are designed to guide a patient through the healthcare system and reduce barriers to timely screening, follow-up, diagnosis, treatment, and supportive care. The PN services in this trial have been tailored for the tribal communities in western Washington state. The services are designed to help participants overcome the unique barriers that their tribal communities face and improve the uptake of LCS.",[34],"2026-06-04",{"date":232,"type":43},"2026-06-05",{"date":42,"type":22},{"date":235,"type":22},"2029-04-30",{"name":165,"class":76},2,{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":254,"leadSponsor":256,"locationsCount":77},"100605982","phase-2-testing-the-survaxm-vaccine-for-lung-cancer-prevention-100605982","NCT07169617","Testing the SurVaxM Vaccine for Lung Cancer Prevention","Evaluating the Feasibility of a Survivin Peptide Vaccine (SurVaxM) as an Interception Agent in Patients at High Risk for Lung Cancer","Inclusion Criteria:\n\n* Former and current smokers (male and female) with a \\>= 20 pack year smoking history\n* Prostate, Lung, Colorectal and Ovarian (PLCO)m2012 Lung Cancer Risk Prediction Score \\> 1.34%\n* Participants \\>= 18 years old will be enrolled. Because no dosing or adverse event (AE) data are currently available on the use of SurVaxM in participants \\\u003C 18 years of age, children and adolescents are excluded from this study but will be eligible for future pediatric trials, if applicable\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 1 (Karnofsky \\>= 60%)\n* Platelets \\>= 100,000\u002Fmicroliter\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN)\n\n  * Note: Higher total bilirubin levels (=\\\u003C 3 mg\u002FdL) can be allowed if due to known benign liver condition, i.e. Gilbert's\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 1.5 x institutional upper limit of normal\n* Serum creatinine =\\\u003C 1.5 x institutional upper limit of normal\n* The effects of SurVaxM plus montanide on the developing human fetus at the recommended therapeutic dose are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* History of autoimmune disease necessitating systemic immunosuppression, immunodeficiency, and\u002For organ allograft\n* Participants may not be receiving any other chemotherapy (except hormonal agents), immunotherapy or investigational agent, or any immunosuppressive agent, including systemic steroids, including those given after organ transplant\n* Participants with current or prior malignancy except for the following:\n\n  * Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years before screening and felt to be at low risk for recurrence by treating physician\n  * Adequately treated carcinoma-in-situ or basal cell carcinoma of the skin without current evidence of disease\n  * Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanomatous skin cancer\n  * Prior or current malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (e.g., localized prostate cancer) may be included\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to montanide or granulocyte-macrophage colony-stimulating factor (GM-CSF)\n* Uncontrolled intercurrent illness, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant women are excluded from this study because of the unknown effects of SurVaxM plus montanide on the fetus. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with SurVaxM plus montanide, breastfeeding should be discontinued if the mother is treated with SurVaxM plus montanide\n* Individuals participating in another interception trial with an immunomodulatory agent will be excluded from participation in this trial for a washout period of 6 months",{"count":246,"type":22},80,[176],"This phase II trial tests how well a survivin peptide vaccine called SurVaxM works in preventing lung cancer in high risk patients. Upon administration, the SurVaxM vaccine activates the immune system to produce an immune cell response against cancer cells that express a protein called survivin. This may result in decreased tumor cell proliferation and lead to tumor cell death. SurVaxM is given with montanide, a substance that helps the immune system respond to the SurVaxM vaccine, followed by sargramostim, which is given to increase the number of white blood cells in the body. The SurVaxM vaccine may help the body make special proteins called antibodies, which may be helpful in preventing the development of lung cancer.",[34],"2026-06-02",{"date":252,"type":43},"2026-06-03",{"date":42,"type":22},{"date":255,"type":22},"2029-09-30",{"name":49,"class":50},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":16,"sex":17,"minAge":109,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":101},"100639583","an-educational-intervention-lung-toolkit-for-improving-knowledge-about-lung-cancer-and-screening-among-american-indian-and-alaskan-native-cigarette-smokers-lung-paths-trial-100639583","NCT07615764","An Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS Trial","Lung Health Promotion for AI\u002FAN People Through Human Center Design (Lung PATHS) - Aim 3 Intervention","Inclusion Criteria:\n\n* Between ages 50-80\n* Self-identify as AI\u002FAN\n* Self-reported 10 pack-year smoking history (commercial tobacco i.e. cigarettes)\n* Ability to understand and willingness to sign an informed consent document\n\nExclusion Criteria:\n\n* Not between ages 50-80\n* Having less than a 10 pack-year history of smoking commercial tobacco\n* Inability to communicate in written and verbal English\n* Having any cognitive impairment that compromises the ability to provide informed consent","80 Years",{"count":266,"type":22},60,[25],"This clinical trial evaluates the acceptability and effectiveness of an educational intervention (Lung Toolkit) for improving knowledge about lung cancer and lung cancer screening among American Indian\u002FAlaskan Native (AI\u002FAN) cigarette smokers. The Lung Toolkit is an educational intervention, including a website and a physical artifact pouch, specifically tailored to the needs of AI\u002FAN individuals. The website includes evidence-based resources about lung health and lung cancer screening, facts about commercial tobacco and traditional tobacco, national and local smoking cessation and screening resources, and community-building resources such as stories from AI\u002FAN community members about their experiences with lung cancer screening and smoking cessation. The physical artifact pouch links to the website with a quick response code and contains ceremonial herbs and motivational messaging around smoking cessation and lung cancer screening. The Lung Toolkit intervention may be effective for improving knowledge about lung cancer and lung cancer screening among AI\u002FAN cigarette smokers.",[34],"2026-05-28",{"date":272,"type":43},"2026-05-29",{"date":274,"type":22},"2026-11-01",{"date":276,"type":22},"2027-05-31",{"name":165,"class":76},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":101},"100500894","stereotactic-body-radiation-therapy-planning-with-artificial-intelligence-directed-dose-recommendation-for-treatment-of-primary-or-metastatic-lung-tumors-rad-ai-study-100500894","NCT05802186","Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study","A Single-Arm Phase II Study of Personalized Dose Guidance for Stereotactic Body Radiotherapy (SBRT) in Patients With Lung Tumors","Inclusion Criteria:\n\n* Patients with radiographic findings consistent with lung cancer or solitary or oligometastatic disease in the lung. Most patients will have primary non-small cell lung cancer. For primary lung cancers, we include lesions with ground glass opacities with a solid component of 50% or greater. Patients with solitary or oligo-metastatic disease in the lung may have any other histology or cancer type.\n* Patients must have radiographically measurable or evaluable disease per RECIST v. 1.1.\n* Patients must be age \\>= 18 years.\n* Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Patients of child-bearing potential (POCBP) must have a negative urine or serum pregnancy test prior to registration on study.\n\n  * NOTE: A POCBP is any person with an egg-producing reproductive tract (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n    * Has not undergone a hysterectomy or bilateral oophorectomy\n    * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n* Radiation therapy is known to be teratogenic. Patients of child-bearing potential (POCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from time of informed consent, for the duration of study participation, and for 7 days following completion of therapy. Should a patient become pregnant or suspect they are pregnant while they or their partner are participating in this study, they should inform their treating physician immediately. People who can impregnate their partners treated or enrolled on this protocol must also agree to use adequate contraception from time of informed consent, for the duration of study participation, and 90 days after completion of administration.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document. Informed consent must be signed prior to registration on study.\n\nExclusion Criteria:\n\n* Patients who have had prior radiotherapy with radiation field overlap.\n* For primary lung cancers, patients with ground glass opacities without a solid component will be excluded.\n* Patients who have not recovered from adverse events confined to the thorax (i.e. pneumonitis, bronchial insufficiency, bronchial hemorrhage, esophagitis) due to prior anticancer therapy (i.e., have residual toxicities \\>= grade 2) with the exception of alopecia. low blood counts (neutropenia, anemia, etc), or anatomically distinct toxicities (i.e. cystitis).\n* Patients who are receiving any other concurrent investigational agents or genotoxic chemotherapy for cancer treatment.\n\n  * Note: Patients receiving targeted therapies are permitted to enroll on the study. However, patients must pause treatment with targeted therapy 3 days prior to SBRT and restart medication at least 2 days after SBRT. Concurrent immunotherapy (if not investigational) is permitted. Coronavirus disease 2019 (COVID-19) vaccinations are allowed.\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible:\n\n  * Ongoing or active infection requiring systemic treatment\n  * Unstable angina pectoris\n  * Stage 3 or greater idiopathic pulmonary fibrosis\n  * Cardiac arrhythmia\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints\n* Female patients who are pregnant or nursing. Pregnant women are excluded from this study because radiation therapy has teratogenic or abortifacient effects.",{"count":286,"type":22},70,[25],"This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation therapy (SBRT) planning in patients with primary lung cancer or tumors that has spread from another primary site to the lung (metastatic). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Even with the high precision of SBRT, disease persistence or reappearance (local recurrence) can still occur, which could be attributed to the radiation dose. AI has been used in other areas of healthcare to automate and improve various aspects of medical science. Because the relationship of dose and local recurrence indicates that dose prescriptions matter, decision support systems to help guide dose based on personalized prediction AI algorithms could better assist providers in prescribing the radiation dose of lung stereotactic body radiation therapy treatment.",[34,290,291,179,184,188],"Lung Non-Small Cell Carcinoma","Metastatic Malignant Neoplasm in the Lung","2026-05-26",{"date":272,"type":43},{"date":295,"type":43},"2023-11-20",{"date":297,"type":22},"2031-08-01",{"name":299,"class":76},"Northwestern University",{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":16,"sex":17,"minAge":109,"maxAge":152,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":101},"100491455","support-and-outreach-to-increase-screening-for-lung-cancer-in-patients-with-a-history-of-smoking-100491455","NCT05679349","Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking","Provider Support and Patient Outreach in Lung Cancer Screening","Inclusion Criteria:\n\n* PRACTICE LEVEL:\n* Primary care practice (family medicine, geriatrics, internal medicine) in one of the 4 participating health systems\n* Practice using the main electronic medical record (EMR) of each system, in order to run appropriate patient recruitment reports\n* Practice with at least 50% of practice providers (physicians and advanced care providers) consenting to participate\n* PATIENT LEVEL:\n* Have an office or telemedicine established patient visit scheduled with a primary care provider in one of the participating practices within next 14 to 25 days\n* 50 to 77 years of age\n* Have at least a 20-pack-year smoking history (based on self-report at baseline eligibility assessment)\n* Currently smoke or have quit smoking within the past 15 years (based on self-report at baseline eligibility assessment)\n* Able to communicate in English or Spanish (determined at baseline eligibility assessment)\n\nExclusion Criteria:\n\n* PATIENT OUTREACH:\n* Any lung computed tomography (CT) or low-dose computed tomography (LDCT) scan in the past 11 months, current procedural terminology (CPT) Codes are as follows\n\n  * G0297 - LDCT screening\n  * 71250 - CT w\u002Fo contrast\n  * 71260 - CT w\u002F contrast\n  * 71270 - CT with and w\u002Fo contrast\n  * 71275 - CT angiography chest\n  * 78815 - Positron emission tomography computed tomography (PET CT) skull base to mid-thigh\n  * 78816 - PET CT whole body\n* Prior history of lung cancer (The patient's problem list includes a problem with an international classification of diseases (ICD10) code of \"Z85.118\" or one beginning with \"C34.\", or by self-report at baseline eligibility assessment)\n* Recent hospitalization (Admission date within the last 60 days listed in electronic health record (EHR), or by self-report at baseline eligibility assessment)\n* Dementia (diagnosis codes F03.90 or F03.91) in EHR",{"count":308,"type":22},822,[25],"This clinical trial tests how well providing education improves screening for lung cancer in patients with a history of smoking. Screenings may help doctors find lung cancer sooner when it may be easier to treat. Education and counseling may be an effective method to help providers and patients learn about lung cancer screening. Providing education and decision counseling to providers and patients may increase lung cancer screening.",[34,312],"Tobacco-Related Carcinoma",{"date":272,"type":43},{"date":315,"type":43},"2024-04-01",{"date":317,"type":22},"2027-02-26",{"name":319,"class":76},"Ronald Myers",{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":101},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":328,"type":22},27,[176],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[332,333,334,28,29,335,30,336,337,338,90,209,339,340,341,34,35,342,343,344,345,346,36,37,347,38,348,349,350],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Cervical Carcinoma","Endometrial Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Hodgkin Lymphoma","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Primary Peritoneal Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma","2026-05-15",{"date":353,"type":43},"2026-05-18",{"date":355,"type":43},"2025-12-18",{"date":357,"type":22},"2026-12-18",{"name":359,"class":76},"Mayo Clinic",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":19,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":382},"100594456","phase-2-a-study-of-skb518-in-patients-with-lung-cancer-100594456","NCT07019675","A Study of SKB518 in Patients With Lung Cancer","A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of SKB518 in Patients With Lung Cancer","Inclusion Criteria:\n\n1. Age between 18 and 75 years old at the time of signing the informed consent form, applicable to both males and females.\n2. Non-small cell lung cancer (NSCLC) or small cell lung cancer(SCLC) confirmed by histology or cytology.\n3. At least one measurable tumor lesion per RECIST v1.1.\n4. Performance status score of 0-1 according to the Eastern Cooperative Oncology Group (ECOG) scale.\n5. Expected survival period ≥ 12 weeks.\n6. The function of important organs meets the requirements of the protocol.\n\nExclusion Criteria:\n\n1. Symptomatic or uncontrolled cardiovascular disease\n2. History of noninfectious pneumonitis\u002Finterstitial lung disease (ILD) that required steroids or has current pneumonitis\u002FILD;\n3. Subjects with the disease that requires systemic corticosteroid therapy (prednisolone or equivalent dose of similar drugs at a dose of \\>10 mg\u002Fd) or other immunosuppressive therapy within 14 days before the first dose.\n4. Human immunodeficiency virus (HIV) positive or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.\n5. The Investigator considers other situations that will interfere with the evaluation of the study intervention or the safety of the subjects or the interpretation of the results of the study.",{"count":368,"type":22},192,[176],"This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer. Eligible subjects will receive SKB518 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.",[34],"2026-05-05",{"date":374,"type":43},"2026-05-08",{"date":376,"type":43},"2025-08-29",{"date":378,"type":22},"2027-10-20",{"name":380,"class":381},"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","INDUSTRY",17,{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":403,"locationsCount":101},"100573209","novel-input-screening-tool-to-improve-illness-understanding-in-patients-with-metastatic-or-incurable-lung-cancer-100573209","NCT06743308","Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer","Information Needs, Preferences, and Understanding Trial (INPUT): A Randomized, Controlled Trial of the Effects of a Screening Tool on Illness Understanding","Inclusion Criteria:\n\n* Within 3 months of biopsy-confirmed diagnosis of stage IV lung cancer\n* Age 18 or over\n* English speaking\n* Attending a follow-up visit at the thoracic medical oncology clinic\n* Plans to receive or actively undergoing cancer-directed systemic treatment at MD Anderson\n\nExclusion Criteria:\n\n• Diagnosis of cognitive impairment or dementia requiring a surrogate decision maker",{"count":391,"type":22},100,[25],"This clinical trial compares the use of a new screening tool designed to evaluate patients' information needs, preferences, and illness understanding to the usual care to improve illness understanding in patients with lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or for which no curative treatment is currently available (incurable). Goal concordant care is a model of care that aligns a patient's medical care with their values, preferences, and goals. Often, patients may not fully understand their illness and prognosis, but this information is important so that they can make fully informed decisions regarding their care that are consistent with their values, preferences, and goals. Completing the Information Needs, Preferences, and Understanding Trial (INPUT) screening tool may allow for more frequent and regular discussions regarding disease status and treatment goals, ultimately resulting in improved patient illness understanding and goal concordant care for patients with metastatic or incurable lung cancer.",[34,395,396],"Metastatic Lung Carcinoma","Stage IV Lung Cancer AJCC v8","2026-04-28",{"date":399,"type":43},"2026-04-29",{"date":401,"type":43},"2024-12-16",{"date":73,"type":22},{"name":196,"class":76},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":23,"phases":414,"briefSummary":415,"conditions":416,"keywords":428,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":101},"100634739","enhanced-copd-management-in-suspected-lung-cancer-patients-100634739","NCT07543601","Enhanced COPD Management in Suspected Lung Cancer Patients","Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention","ECHELON","Inclusion Criteria:\n\n* Undergoing diagnostic evaluation for suspected lung cancer\n* Spirometry showing obstructive airflow limitation (FEV₁\u002FFVC \\\u003C 75 % or FEV₁ \\\u003C 80 %, and no reversibility) at the first outpatient visit at the lung cancer evaluation\n\nExclusion Criteria:\n\n* Presence of significant comorbidities that may interfere with diagnostic procedures or spirometry\n* Pregnant or breastfeeding women",{"count":413,"type":22},280,[25],"Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates.\n\nThis study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle.\n\nThe findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.",[417,418,419,34,420,421,422,423,424,425,426,427],"COPD (Chronic Obstructive Pulmonary Disease)","Lung Cancer (Diagnosis)","Lung Neoplasm Malignant","Pulmonary Neoplasms","Pulmonary Neoplasm","Pulmonary Cancers","Pulmonary Cancer","Pulmonary Carcinoma","COPD","COPD - Chronic Obstructive Pulmonary Disease","Airflow Obstruction, Chronic",[429,430,431,432],"Invesigation","Evaluation","Diagnostic Work-up","Diagnostic Pathway","2026-04-15",{"date":435,"type":43},"2026-04-22",{"date":437,"type":43},"2026-03-06",{"date":439,"type":22},"2027-06-30",{"name":441,"class":76},"Ditte Krag-Hansen",{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":452,"briefSummary":453,"conditions":454,"keywords":455,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":101},"100422618","walking-after-surgery-to-improve-recovery-and-outcomes-after-surgery-airtech-study-100422618","NCT04783168","Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study","Ambulation to Improve Recovery With Wearable TECHnology (AIRTECH) Study","AIRTECH","Inclusion Criteria:\n\n* 18 years or older\n* English speaking\n* Ambulatory preoperatively\n* Patients undergoing at least a lobectomy\n* Must own a smart phone and be willing to install the Fitbit application (App)\n* Adequate internet connection via wifi or wireless network connection with smartphone\n* Patients who are not already using a wearable device to track daily steps\n\nExclusion Criteria:\n\n* Medical, psychiatric, cognitive or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study.\n* Cannot maintain activity monitor in place at the time of consent\n* Pregnant patients",{"count":451,"type":22},240,[25],"This clinical trial evaluates the relationship between walking and sleeping habits and surgical outcomes in patients with lung cancer. Early walking after surgery is associated with decreased or less severe complications. Learning about how much patients walk may be important in improving outcomes after surgery. Information gained from this trial may help researchers develop interventions to improve outcomes after surgery and improve overall quality of life after surgery in patients with lung cancer.",[34],[456,457,458,459,460,461,462,463,464],"Wearable","device","fitness","tracker","Fitbit","ambulation","lung cancer","surgical","recovery","2026-04-13",{"date":467,"type":43},"2026-04-16",{"date":469,"type":43},"2020-11-30",{"date":471,"type":22},"2027-02-02",{"name":196,"class":76},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":16,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":101},"100408203","educating-smokers-about-lung-cancer-screening-using-tobacco-quitlines-100408203","NCT04595422","Educating Smokers About Lung Cancer Screening Using Tobacco Quitlines","Inclusion Criteria:\n\n* QUITLINE CALL CENTER STAFF\n* Staff member of a quitline\n* Aged 18 years and above\n* CALLERS (SMOKERS WHO CONTACT THE QUITLINE ABOUT SMOKING CESSATION SERVICES) INCLUSION CRITERIA\n* Callers 55-80 years of age\n* Current smoker, or former smoker with a cessation history of \\\u003C 15 years\n* \\>= 30 pack-year smoking history\n* English-speaking\n\nExclusion Criteria:\n\n* CALLERS (SMOKERS WHO CONTACT THE QUITLINE ABOUT SMOKING CESSATION SERVICES) EXCLUSION CRITERIA\n* History of lung cancer by self-report",{"count":480,"type":22},800,[25],"This implementation study will examine the best ways to refer heavy smokers to information about lung cancer screening.",[34],{"date":467,"type":43},{"date":486,"type":43},"2020-07-02",{"date":488,"type":22},"2026-10-31",{"name":196,"class":76},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":16,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":23,"phases":500,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":507,"leadSponsor":509,"locationsCount":101},"100614657","a-new-way-to-share-radiation-therapy-plans-between-doctors-correct-trial-100614657","NCT07282444","A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial","Collaborative Oncology Between Radiologists and Radiation Oncologists for the Evaluation of Contoured Targets (CORRECT)","CORRECT","Inclusion Criteria:\n\n* PRACTICE: Must provide radiation therapy for ≥ 3 patients per month with lung cancer or head \\& neck cancer\n* PRACTICE: At least one radiation oncologist and one radiologist (in house, contracted, etc.) at the practice willing to participate, but may have multiple participants at the practice\n* PRACTICE: Radiation oncologist\u002Fradiologist team must use Picture Archiving and Communication System (PACS) software at this practice\n* RADIATION ONCOLOGIST (NON-PATIENT): Must have been in independent practice (i.e., performing duties without preceptor oversight) for a minimum of six months\n* RADIATION ONCOLOGIST (NON-PATIENT): Must treat lung and\u002For head \\& neck cancer patients with curative intent radiation therapy\n* RADIATION ONCOLOGIST (NON-PATIENT): Willing and able to participate in 15 minutes of mandatory virtual CORRECT training\n* RADIATION ONCOLOGIST (NON-PATIENT): Willing to participate in a 30-minute interview, if selected at the end of the study\n* RADIOLOGIST (NON-PATIENT): Must have been in independent practice (i.e., performing duties without preceptor oversight) for a minimum of six months\n* RADIOLOGIST (NON-PATIENT): Agree to review pre-treatment radiation therapy targets during the course of the study duration (approximately 12 months). Willing and able to participate in 15 minutes of mandatory virtual CORRECT training\n* RADIOLOGIST (NON-PATIENT): Willing to participate in a 30-minute interview, if selected at the end of the study\n* PATIENT: Must have any stage of clinically diagnosed lung or head \\& neck (HN) cancer\n* PATIENT: Planned treatment with curative intent definitive RT (with or without other treatments). Curative intent RT must be documented in the electronic medical record (EMR) by the treating radiation oncologist\n* PATIENT: Must be expected to be treated by a radiation oncologist participating in this study\n* PATIENT: Must be 18 years or older\n\nExclusion Criteria:\n\n* PRACTICE: Participation by the Community Site or Minority\u002FUnderserved Community Site in another National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Cancer Care Delivery Research (CCDR) U34-supported protocol funded in NCI fiscal year 2025 or later. (Note: WF- 2301CD CONNECT is exempt from this policy, as it was funded prior to NCI fiscal year 2025.)\n* RADIATION ONCOLOGIST (NON-PATIENT): Planning to leave their position at this practice within the next 12 months\n* RADIATION ONCOLOGIST (NON-PATIENT): Providing service on a temporary basis (i.e., locum tenens providers)\n* RADIOLOGIST (NON-PATIENT): Planning to leave their position at this practice within the next 12 months\n* RADIOLOGIST (NON-PATIENT): Providing service on a temporary basis (i.e., locum tenens providers)\n* PATIENT: Unable to understand English or Spanish\n* PATIENT: Early glottic larynx cancer planned for definitive RT alone",{"count":499,"type":22},194,[25],"This clinical trial tests a new way to share radiation therapy plans using the Collaborative Oncology between Radiologists and Radiation oncologists for the Evaluation of Contoured Targets (CORRECT) workflow to improve communication and collaboration between radiation oncologists (ROs) and radiologists when determining cancer targets for radiation treatment. Systemic barriers limit critical communication between radiation oncologists and radiologists and can lead to both under and overdosing of radiation therapy (RT) tumor targets and failures to properly interpret post-treatment imaging. The limited formal diagnostic radiology training of many providers can make differentiating normal from disease imaging findings during target determination difficult, especially in complex disease sites like the lung, head, and neck. Inaccurate target determination may result in cancer return, excess toxicity, or both. Likewise, radiologists who cannot access prior RT plans may mistake expected RT changes for recurrent cancer or overlook true progression. The CORRECT workflow was developed by ROs and radiologists to address RO-radiology communication barriers by facilitating sharing of comprehensive RT target contours during RT planning. The CORRECT workflow begins with the normal process of RO target contouring. Computed tomography (CT) images are then fused with RT targets and pushed to a pre-designated Picture Archiving and Communications System (PACS) software folder accessible by the radiology department. The radiologist can then review the fused images at their chosen time and annotate images to indicate potential deviations (e.g., not avoiding normal tissue or not including all tumor). The RO reviews the annotated images and decides if any changes to treatment targets are needed for the final treatment plan. Through this independent, asynchronous review of high-quality images, CORRECT overcomes many of the limitations of existing communication methods between RO-radiologist, fostering a more collaborative, efficient, and precise approach to cancer treatment planning.",[34,209],"2026-03-20",{"date":505,"type":43},"2026-03-23",{"date":42,"type":22},{"date":508,"type":22},"2028-11-01",{"name":510,"class":76},"Wake Forest University Health Sciences",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":16,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":23,"phases":520,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":531},"100531147","telephone-based-physical-activity-coaching-or-self-monitored-physical-activity-to-improve-physical-function-in-older-adults-who-are-undergoing-surgery-for-lung-cancer-and-their-caregivers-100531147","NCT06196008","Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers","SR2204: A Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults With Lung Cancer and Their Family Caregivers","Inclusion Criteria:\n\n* PATIENT: Documented informed consent of the participant and\u002For legally authorized representative\n* PATIENT: Agreement to allow the use of preoperative chest CT scan for exploratory analysis, if available\n* PATIENT: Agreement to wear pedometer during study duration\n\n  * If unwilling, exceptions may be granted with study primary investigator (PI) approval\n* PATIENT: Age \\>= 65 years\n* PATIENT: Ability to read and understand English or Spanish and willingness to complete participant-reported outcomes and assessments\n* PATIENT: Diagnosis of lung cancer or presumed lung cancer (as determined by surgeons) in patient\n* PATIENT: Scheduled to undergo lung surgery for lung cancer or suspected lung cancer with curative intent (neoadjuvant therapy allowed)\n* PATIENT: Adults lacking capacity to consent in the opinion of the attending surgeon will not be enrolled\n* FCG: Documented informed consent of the participant and\u002For legally authorized representative\n* FCG: Age \\>= 18\n* FCG: Ability to read and understand English or Spanish and willingness to complete participant-reported outcomes and assessments\n* FCG: Adults lacking capacity to consent in the opinion of the attending surgeon will not be enrolled\n\nExclusion Criteria:\n\n* PATIENT: Lung surgery is scheduled in less than 14 calendar days from the time of registration\n* PATIENT: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including exercise program and compliance issues related to feasibility\u002Flogistics)\n* FCG: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including exercise program and compliance issues related to feasibility\u002Flogistics)",{"count":519,"type":22},382,[25],"This clinical trial compares telephone-based physical activity coaching to self monitored physical activity for improving physical function in older adults who are undergoing surgery for lung cancer and their caregivers. Lung cancer surgery in older adults is associated with functional declines and unique challenges. Performing physical activity around the time of surgery has been shown to improve functional outcomes in patients and exercise programs delivered via telehealth may improve access and convenience for patients and minimize participant burden. Telephone-based physical activity coaching may improve physical functioning for older adults with lung cancer who are undergoing surgery.",[34],"2026-03-03",{"date":525,"type":43},"2026-03-05",{"date":527,"type":43},"2023-12-05",{"date":529,"type":22},"2028-05-16",{"name":100,"class":76},16,{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":541,"conditions":542,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":101},"100412007","the-rise-in-robotic-atypical-segmentectomies-100412007","NCT04644952","The Rise in Robotic Atypical Segmentectomies","The Rise in Robotic Atypical Segmentectomies: A Large Cancer Center Experience","Inclusion Criteria:\n\n* Patients who underwent a lung resection from 2004 to 2019",{"count":540,"type":22},600,"This study investigates the increased rate of robotic atypical segmentectomies. Segmentectomy refers to removing a section of a lobe of the lung. Reviewing patients' data retrospectively may help researchers determine whether robotic surgery has led to an increase in atypical segmentectomy.",[34],{"date":525,"type":43},{"date":545,"type":43},"2020-09-15",{"date":547,"type":22},"2027-04-30",{"name":196,"class":76},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":558,"briefSummary":559,"conditions":560,"keywords":566,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":101},"100609797","engagement-of-veterans-with-lung-cancer-100609797","NCT07219251","Engagement of Veterans With Lung Cancer","Engagement of Veterans With Lung Cancer (EVLC)","EVLC","Inclusion Criteria:\n\n1. Veteran patients with diagnosis of any stage of lung cancer;\n2. 18 years of age or older;\n3. English- or Spanish-speaking;\n4. can self-administer questionnaires in English or Spanish;\n5. valid telephone number;\n6. receiving oncology care at participating sites;\n7. currently newly diagnosed or receiving or having completed systemic anti-cancer therapy and\u002For radiation therapy within 12 months, defined as oral, injection, or intravenous therapy (chemotherapy, targeted therapy, or immunotherapy)\n\nExclusion Criteria:\n\n1. no capacity to consent;\n2. actively receiving hospice care",{"count":499,"type":22},[25],"This research study will help our understanding of whether additional support for Veterans with lung cancer can improve their quality of life.",[561,562,563,34,564,565],"Lung Cancer (NSCLC)","Lung Adenocarcinoma","Lung Cancer, Non-Small Cell","Lung Cancer, Small Cell","Lung Adenocarcinoma With Bronchiolo-alveolar Feature",[567,568],"lung","cancer","2026-03-02",{"date":523,"type":43},{"date":572,"type":43},"2026-02-27",{"date":574,"type":22},"2032-12-31",{"name":576,"class":76},"Palo Alto Veterans Institute for Research",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":101},"100553129","molecular-analysis-of-suspected-or-high-risk-lung-cancer-to-drive-individualized-care-interception-for-suspected-lung-cancer-100553129","NCT06482073","Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)","Inclusion Criteria:\n\n* Subject age 18 years and older\n* Subject is scheduled\u002Fwas scheduled for a bronchoscopy as part of standard of care\n* Subject with a moderate to high risk of lung cancer based on clinical demographic and radiologic information or with suspected metastatic disease\n* Ability to provide blood or saliva sample\n* Ability to provide archived tissue\n* Subject is able to understand and adhere to study requirements and able to provide informed consent\n\nExclusion Criteria:\n\n* Individuals who have situations that would limit compliance with the study requirements\n* Institutionalized (i.e. federal medical prison)\n* Pregnant\n* Prior germline genetic testing with a 40+ multi-gene panel within the last 1 year of enrollment\n* Prior somatic tissue (250+ gene) testing within the prior 3 months of enrollment",{"count":584,"type":22},40,"This study evaluates the effectiveness of robotic biopsies in providing information about hereditary or cancer specific genetic variants that may have a role in diagnosis of cancer and to develop genetic results and medical record databank for future studies.",[34,291],"2026-02-24",{"date":572,"type":43},{"date":590,"type":43},"2024-06-24",{"date":592,"type":22},"2027-07-01",{"name":359,"class":76},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":16,"sex":17,"minAge":109,"maxAge":264,"enrollmentInfo":601,"targetDuration":4,"studyType":23,"phases":603,"briefSummary":604,"conditions":605,"keywords":607,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":237},"100508298","lung-cancer-screening-in-high-risk-black-individuals-100508298","NCT05898594","Lung Cancer Screening in High-risk Black Individuals","Evaluating the Feasibility of Lung Cancer Screening in High-risk Black Individuals","Inclusion Criteria:\n\n* Self-identified Black individual.\n* Have a self-reported history of smoking. No restriction will be placed on the number of smoking pack years participants must have nor the number of years former smokers must have quit smoking.\n* Aged 50-80 years.\n\nExclusion Criteria:\n\n* Individuals with a history of lung cancer.\n* Individuals with symptoms suggestive of lung cancer. We will evaluate whether individuals have symptoms suggestive of lung cancer by administering an online screening questionnaire, which will ask whether they have experienced shortness of breath, whether they become easily winded, and whether they have had a chronic cough within the last 12 weeks that has not improved. Individuals who select that they have any one of these symptoms will be advised to follow up with their primary doctor and will not be eligible to participate in the study.\n* Individuals with pneumonia or acute respiratory infection within 12 weeks prior to enrollment that was treated with antibiotics.",{"count":602,"type":22},900,[25],"The goal of this research study is to study U.S. Black individuals with a history of smoking to examine the feasibility, acceptability, and performance of low-dose computed tomography (LDCT) screening among this population.\n\nThe name of the intervention used in this research study is:\n\nLow-dose computed tomography (radiologic scan) chest scan",[606,34],"Lung Cancer",[606,34],"2026-02-20",{"date":610,"type":43},"2026-02-23",{"date":612,"type":43},"2023-09-06",{"date":614,"type":22},"2028-06-30",{"name":616,"class":76},"Massachusetts General Hospital"]